BioNTech Faces a Pivotal Week as EMA Expands Vaccine Reach and Pipeline Data Fuels Oncology Ambitions

BioNTech enters a critical stretch with Q1 earnings, EMA label expansion for Comirnaty, advancing oncology pipeline, and founders' planned exit by 2026.

BioNTech enters a defining stretch of the year with a packed calendar: first-quarter earnings due May 5, a shareholder meeting on May 15, and a steady drumbeat of clinical and regulatory developments. The biotech is trying to balance a shrinking COVID franchise against an ambitious oncology transformation, all while preparing for a leadership transition that will reshape the company.

EMA Lowers Comirnaty Age Threshold

On April 27, the European Medicines Agency’s CHMP recommended expanding Comirnaty’s label to children as young as six months. The decision covers all 10-microgram formulations targeting variants JN.1, KP.2, and LP.8.1. Previously, the lower age limit was five years.

The updated regimen for infants and toddlers aged six months to four years who lack a completed primary series calls for three doses: the first two given three weeks apart, with the third at least eight weeks after the second. While not a blockbuster catalyst, the move broadens BioNTech’s addressable market for its COVID vaccine at a time when pandemic-era demand has cooled sharply.

Oncology Pipeline Takes Center Stage

The real story for BioNTech lies in its cancer pipeline. Data presented at the European Lung Cancer Congress in March highlighted Pumitamig (BNT327), a bispecific immune modulator, as the company’s lead oncology candidate. In a Phase 1b/2a study conducted in China, the drug showed antitumor activity as a monotherapy regardless of PD-L1 expression levels. More striking were results from a separate analysis: a 53.3% response rate and median overall survival of 27 months in certain lung cancer patients.

BioNTech is now running seven Phase 3 studies with Pumitamig in first-line non-small cell lung cancer alone. The company’s broader goal is to have 15 active Phase 3 oncology trials by the end of 2026. That aggressive timeline reflects the urgency to build a revenue stream beyond COVID before vaccine sales dwindle further.

Competition is fierce. Merck’s rival candidate MK-2010 posted response rates of 55% and 44% in its own Phase 1/2 studies, setting a high bar for BioNTech’s candidate.

Analyst Opinions Split Ahead of Earnings

Wall Street remains divided on BioNTech’s prospects. Leerink Partners recently trimmed its price target, citing concerns around the CTLA-4 antagonist Gotistobart. Other firms point to the strength of the late-stage pipeline as a reason for optimism.

For the first quarter of 2026, analysts expect BioNTech to report a loss per share of roughly $2.54 on revenue of about $220 million. The numbers underscore the company’s heavy investment in R&D as it pivots away from COVID dependence.

Leadership Change Looms

Adding to the uncertainty, founders U?ur ?ahin and Özlem Türeci plan to exit BioNTech by the end of 2026 to launch a new venture focused on next-generation mRNA technology. BioNTech will retain a minority stake and rights to future milestones from that spin-off.

The annual general meeting on May 15 will address governance changes tied to this transition. Shareholders will vote on expanding the supervisory board from six to eight members and authorizing new capital for 2026.

Regional Biotech Push

Separately, BioNTech’s home region is getting a strategic boost. On April 24, the cities of Heidelberg and Mainz signed a memorandum of understanding to develop the Neckar-Rhein-Main corridor into a leading biotech hub. The initiative aims to improve conditions for medical biotechnology, clinical trials, and capital access. Mainz, where BioNTech is headquartered, sits at the center of mRNA innovation.

Stock Action Reflects Uncertainty

BioNTech’s shares have been volatile. The stock traded at €87.50 recently, just below its 200-day moving average of €87.79. It has rallied nearly 18% over the past month but dropped about 7% in the last seven days — a pattern that suggests investors are hedging bets ahead of the earnings release.

The stock remains roughly 15% below its 52-week high but has recovered significantly from a March low of €72.50. The May 5 earnings call, scheduled for 2:00 PM CET shortly before the US market opens, will offer the clearest picture yet of how quickly BioNTech’s oncology pipeline can offset the COVID revenue decline.